Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Curis (CRIS) reported a quarterly loss of $0.49 per share, better than the Zacks Consensus Estimate of a loss of $0.62, and an improvement from a loss of $1.7 per share a year ago, resulting in an earnings surprise of +20.97% [1] - The company generated revenues of $3.18 million for the quarter ended September 2025, exceeding the Zacks Consensus Estimate by 8.58% and showing growth from $2.93 million in the same quarter last year [2] - Curis has surpassed consensus EPS estimates three times over the last four quarters and has topped consensus revenue estimates four times during the same period [2] Financial Performance - Curis shares have declined approximately 53.6% year-to-date, contrasting with the S&P 500's gain of 15.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.62 on revenues of $3.06 million, while for the current fiscal year, the estimate is -$2.60 on revenues of $11.05 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Curis belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5][6]